Théa signs a new agreement for the acquisition of a range of 7 ophthalmic products from Akorn Operating Company LLC, an American company based in Illinois. This agreement will enable Théa to become a leading supplier of eye care products, all approved by the Food and Drug Administration (FDA), which represent cumulative turnover of about $60M:
AcellFx (amniotic membrane for the ocular surface)
AzaSite® (conjunctivitis bacterial)
Akten® (local anaesthetic).
Théa will also welcome a sales force of nearly 50 people from Akorn, to support planned growth and additional product launches in the United States.
This agreement is a key and strategic step in the development of Théa to prepare and support the next launches of the Théa product line in the USA.